EDMONTON, Nov. 7 /CNW/ - Biomira Inc. (Nasdaq: BIOM) (TSX: BRA) today
announced that Robert Aubrey, Vice-President Marketing and Business
Development, is to present at the Bio-Europe 2005 meeting being held in
Dresden, Germany. Mr. Aubrey's partnering presentation is scheduled to be held
on November 8, 2005 at 5:45 CET.
Mr. Aubrey's presentation will focus on in-licensing opportunities sought
by Biomira as well as out-licensing opportunities:
- Liposomal Interleukin-2 (L-IL-2), available through Oncodigm BioPharma
Inc., Biomira's spin-off company;
- Biomira's synthetic adjuvants; and
- Biomira's early stage licensing opportunity, BGLP40 Liposome Vaccine
(L-BGLP40).
Mr. Aubrey will also highlight data announced last week on the Company's
lead product candidate, BLP25 Liposome Vaccine (L-BLP25), a MUC1-based
liposomal vaccine program in non-small cell lung cancer (NSCLC). Data from a
phase 2b study show that patients with Stage IIIB locoregional NSCLC have a
median survival of 30.6 months for the vaccine arm compared to 13.3 months for
those not receiving the vaccine. The Company expects to initiate a phase 3
trial in 2006, in conjunction with its collaborator for L-BLP25, Merck KGaA of
Darmstadt, Germany.
Biomira Inc.
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's commitment
to the treatment of cancer currently focuses on the development of synthetic
vaccines and novel strategies for cancer immunotherapy.
This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements, including those predicting the timing of the
L-BLP25 phase 3 trial or the Company's ability to resolve vaccine
manufacturing issues in a reasonable timeframe. Although the Company believes
that the forward-looking statements contained herein are reasonable, it can
give no assurance that the Company's expectations are correct or that the
Company will have sufficient resources to fund clinical trials. All
forward-looking statements are expressly qualified in their entirety by this
cautionary statement.
BIOMIRA INC. 2011 - 94 St. Edmonton, AB, Canada T6N 1H1
Tel: (780) 450-3761 Fax: (780) 463-0871
http://www.biomira.com
